Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:CRVS) 2026-06-05